The Alliance for Artificial Intelligence in Healthcare commends the recent joint publication by the FDA's Centers for Biologics Evaluation and Research (CBER), Drug Evaluation and Research (CDER), Devices and Radiological Health (CDRH), and the Office of Combination Products (OCP). This article outlines four key recommended areas of focus, and underscores the transformative potential of AI in healthcare while highlighting the crucial steps needed to ensure we safely harness this potential. This is one of the key missions of the Alliance for AI in Healthcare.

At a post-JPM roundtable, AAIH members distilled several key 2024 predictions and takeaways.

Amidst the tumult of the first quarter of 2023, marked by macroeconomic headwinds, banking crises, and a sluggish biotech economy, one topic with its hype and truths has captured the imagination of the masses more than any other: Artificial intelligence (AI).